A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...

Merck’s Keytruda is the world’s top-selling drug, bringing in nearly $30 billion in sales last year. The drug, which is used to treat lung cancer, melanoma and certain other cancers, has historically ...

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...